A blinded prospective study was performed to determine whether screening of whole blood using a real-time, panfungal polymerase chain reaction (PCR) technique could predict the development of invasive fungal infection (IFI) in immunocompromised haemato-oncology patients. In all, 78 patients (125 treatment episodes) were screened twice weekly by real-time panfungal PCR using LightCyclert technology. IFI was documented in 19 treatment episodes (five proven, three probable and 11 possible), and in 12, PCR was sequentially positive. PCR positivity occurred in: 4/5 proven; 2/3 probable; 6/11 possible; and 29/106 with no IFI. In 8/12 with IFI and sequentially positive PCR results, PCR positivity occurred before (median 19.5 days) and in 4/12 (median 10.5 days) after the initiation of empirical antifungal therapy. Based on sequential positive results for proven/probable IFI sensitivity, specificity, positive predictive value and negative predictive value were 75, 70, 15 and 98%, respectively. Real-time panfungal PCR is a sensitive tool for the early diagnosis of IFI in immunocompromised haemato-oncology patients. It may be most useful as a screening method in high-risk patients, either to direct early pre-emptive antifungal therapy or to determine when empirical antifungal therapy can be withheld in patients with antibiotic-resistant neutropenic fever. However, these strategies require further assessment in comparative clinical trials.
plant; invasive fungal infection; polymerase chain reaction Invasive fungal infections (IFI) are the leading cause of infectious death in stem cell transplantation (SCT) and chemotherapy-induced myelosuppression, and early initiation of antifungal therapy is critical in improving therapeutic outcome. [1] [2] [3] [4] [5] However, clinical and radiological manifestations of IFI are nonspecific, and seldom apparently early, current laboratory diagnostic techniques are insensitive and the performance of invasive diagnostic procedures is often precluded by profound cytopenia. [6] [7] [8] [9] [10] This diagnostic uncertainty has led to the widespread use of empirical antifungal therapy in patients with antibiotic-resistant neutropenic fever (ARNF). 11 However, fever is a nonspecific sign with multiple aetiologies and this strategy results in unnecessary treatment with potentially toxic and prohibitively expensive antifungal therapy.
It is clear that, if mortality due to IFI is to be reduced, new, pre-emptive therapeutic strategies will be required, which will depend on the availability of rapid, sensitive diagnostic methods. Recently, methods for the serological and molecular diagnosis of IFI in blood and bronchoalveolar lavage (BAL) have been developed. Among the techniques based on antigen detection, the commercially available sandwich enzyme-linked immunosorbent assays (ELISA) for the detection of circulating aspergillus galactomannan (GM) 12 and candida mannan (M) (fungal cell wall components) (Platelia s Aspergillus and Platelia s Candida) are currently the most promising. [13] [14] [15] [16] In particular, the GM ELISA has been shown to be sensitive and specific for the early diagnosis of invasive aspergillosis (IA), [17] [18] [19] [20] [21] and antigen detection is now included in the European Organisation for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) guidelines as one of the criteria for diagnosis of IA 22 and has been approved by the United States Food and Drug Administration (FDA).
Polymerase chain reaction (PCR)-based assays utilising panfungal primers, which target highly conserved multicopy gene sequences, and hybridisation with specific oligonucleotide probes enable detection of a wide range of yeasts and moulds with a sensitivity of 1-10 fg/ml. [23] [24] [25] [26] [27] [28] Sensitivity approaching 100% has been documented in several prospective clinical studies, with two consecutive positive results being strongly associated with the development of IFI. Sequential PCR positivity has preceded both clinical signs and symptoms and clinical diagnosis by several days. 21, [29] [30] [31] Real-time PCR assay using the LightCyclert technique 32 combines rapid amplification, probe hybridisation and signal generation in a single tube, allowing quantification of fungal DNA while retaining sensitivity. Although this technique has been evaluated in other studies, it has either been assessed retrospectively or has utilised specific Candida albicans and/or Aspergillus fumigatus probes. To our knowledge, real-time panfungal PCR utilising the LightCyclert technique has not been prospectively evaluated in at-risk haemato-oncology patients.
This blinded study prospectively assessed the value of screening of whole-blood specimens from haemato-oncology patients at high risk of IFI using real-time PCR.
Patients, materials and methods

Study population
Approval for the study was obtained from the relevant Hospital Ethics Committees. Full informed consent was obtained from all patients recruited.
From December 2000 to December 2001, all adult patients receiving allogeneic SCT, autologous SCT conditioned with TBI or colonised with yeasts, or intensive chemotherapy for haematological malignancy were prospectively enrolled in the study. A treatment episode was defined as a single course of chemotherapy or an autologous SCT, starting on the first day of cytotoxic chemotherapy and ending with either neutrophil recovery (X1 Â 10 9 /l) or hospital discharge, or an allogeneic SCT, starting on the first day of pre-transplant conditioning therapy until day 100 following the transplant, unless steroids were administered for the treatment of graftversus-host disease (GVHD), in which case, the start of corticosteroids marked the beginning of second episode and sampling continued until immunosuppression was discontinued.
Patient management and case definitions
Antifungal prophylaxis, consisting of fluconazole (100 mg/ day) or itraconazole (5 mg/kg/day, dose adjusted to a level of 4500 ng/ml), was given according to local protocols. Systemic antibiotic therapy at the onset of neutropenic fever was based on standard protocols after clinical examination and chest radiography (CXR) were performed and appropriate specimens obtained for microbiological investigations. Empirical antifungal therapy (amphotericin B at a dose of 1 mg/kg or liposomal amphotericin B (AmBisome s ) at a dose of 3 mg/kg if renal function deteriorated) was started in cases of ARNF. A full diagnostic work-up including culture of clinical specimens, CXR and/or computed tomography (CT) scanning was performed. BAL was performed at the discretion of the attending physician. All physicians caring for the patients were blinded to the PCR results.
IFI was classified as proven, probable or possible according to EORTC/MSG definitions. 22 As one of the EORTC/MSG criteria, GM antigen was measured twice weekly using the Platelia s Aspergillus ELISA. According to the manufacturer's instructions and EORTC/MSG IFI definitions, a GM index of 41.5 on two consecutive occasions was considered as a true positive.
Collection and handling of blood specimens
Samples of EDTA (4-5 ml) blood were collected twice weekly (Monday and Thursday) for the duration of each treatment episode. All PCR assays were performed at Glasgow Royal Infirmary by an investigator blinded to clinical and microbiological data. Blood samples from Edinburgh were transported overnight at ambient temperature, then stored at 41C and processed within 48 h.
PCR assay
DNA was extracted, from 4 ml of blood, as described previously. 28 Blood from a healthy volunteer was extracted concurrently as a negative control with every 11 patient samples. As positive extraction controls, and to determine the sensitivity of the assay, standards prepared from wholeblood spiked with aspergillus spores/candida cells were included (10 0 -10 6 cells/spores/ml). All work was carried out in a secondary class extraction hood and DNA extraction and PCR set-up were performed in separate laboratories.
Primers described previously 32 were used to amplify a conserved region of the fungal 18 s rRNA gene. Panfungal oligonucleotide hybridisation probes (3FL-TTC AAC TAC gAg CTT TTT AAC Tg and LC Red640-AAC AAC TTT AAT ATA CgC TAT Tgg A (Tib MOLBIOL, Berlin, Germany)) (Loeffler, personal communication, 2000) were used to bind to a common sequence present in all fungal species. The PCR was performed in a Roche realtime LightCyclert (Roche, East Sussex, UK) and comprised 60 cycles of denaturation for 15 s at 951C, annealing for 10 s at 551C and extension for 25 s at 721C, followed by a melting curve analysis step of a single cycle of 20 s at 951C, 20 s at 451C (slope 11C/s) and 1 s at 951C (slope 0.21C/s). Melting curve analysis was used to determine if the PCR was positive or negative. A peak at B571C indicated the presence of candida, and at B601C, aspergillus species. Each sample was assayed in duplicate with positive standards and negative controls and all positive samples were repeated for confirmation. This technique could detect a lower limit of 10 CFU/ml C. albicans and 20 CFU/ml of A. fumigatus. True positivity was defined by at least two consecutive positive results.
Data analysis
Data were entered into, and managed, in a Microsoft Access database. PCR results were correlated with EORTC/MSG evidence of IFI. We determined the temporal relationship between PCR positivity and initiation of empirical antifungal therapy. Initiation of antifungal therapy was chosen as a comparator to PCR positivity in preference to fever or CT evidence of IFI, as fever represents an early but nonspecific sign of infection, while CT evidence of IFI is usually obtained later in the course of ARNF, at the time of, or after the initiation of antifungal therapy.
Results
Patient cohort
A total of 78 patients, aged 16 to 76 years (mean 42, median 44.5), comprising 125 treatment episodes was recruited. Episode type and underlying diagnosis for the chemotherapy episodes are shown in Table 1 .
Retrospective (Table 2) .
Of the 41 treatment episodes in which sequential positive PCR results were recorded, EORTC/MSG-defined IFI was documented in 12/41 (29%) ( Table 2 ). In eight of these 12 episodes, sequential PCR positivity occurred between 1 and 69 days (mean 13, median 19.5) before, and in the other four, between 3 and 24 days (mean 12, median 10.5) after the initiation of antifungal therapy (Table 3) . In a further 29 of the 41 episodes with sequentially positive PCR results, there was no evidence of IFI. In 22 of the 29 episodes, neutropenia was present at the time of sequential PCR positivity. In 11 of the 22 episodes, sequential PCR positivity resolved concurrent with neutrophil recovery, in eight whilst still neutropenic and in a further three following neutrophil recovery. Five of the 22 went on, in subsequent neutropenic episodes, to develop IFI (two proven, one probable and two possible). Two of the five (one possible and one probable) had received empirical antifungal therapy during the previous treatment episode. In seven of 29 episodes, sequential PCR positivity did not coincide with neutropenia (five allogeneic SCTs following engraftment, with no evidence of GVHD, one allogeneic SCT following engraftment and receiving steroids for GVHD and one chemotherapy episode between phases I and II of induction therapy for ALL).
In the four patients with proven IFI who were sequentially PCR positive, PCR positivity occurred prior to both the microbiological diagnosis and the administration of empirical antifungal therapy (Table 3 ). In the other episode of proven IFI, a single positive PCR was obtained on the same day as a positive blood culture for a Candida spp and subsequently became negative with antifungal therapy. Three treatment episodes had evidence of probable IFI, in two of which, sequential positive PCR results were recorded (Table 3) .
Using sequential positive PCR results, the sensitivity for proven, proven/probable and proven/probable/possible IFI was 80, 75 and 63%, respectively. The specificity for proven, proven/probable and proven/probable/possible was 69, 70 and 62%, respectively. The positive predictive value (PPV) for proven/probable IFI was 15%; inclusion of possible IFI increased this to 23%. The negative predictive value (NPV) for proven IFI was 99% and for proven/probable IFI was 98%.
Discussion
We have described a screening programme to evaluate the use of real-time panfungal PCR for the early diagnosis of IFI in at risk haemato-oncology patients. The results indicate that detection of fungal DNA using real-time PCR represents a significant advance in the diagnosis of IFI. The difficulties in establishing a definitive diagnosis of IFI have prompted the development of the EORTC/MSG criteria for IFI; however, only proven IFI represents a robust diagnosis. While studies may calculate sensitivity, specificity, PPV and NPV for proven, probable and possible IFI, it must be recognised that many cases of possible and even probable IFI may be due to non-fungal causes. For example, of the 12 cases of EORTC/MSG defined IA in this study, there were no cases of proven, only one case of probable and 11 cases of possible infection. This highlights the current difficulty in obtaining a definitive diagnosis of IA in this patient population and the need for new diagnostic methods. According to EORTC/MSG definitions, even the highly suggestive CT halo sign only defines possible IA, unless there is microbiological evidence of IA such as culture of Aspergillus spp from BAL fluid. Maertens et al demonstrated, after incorporation of autopsy data, that 12 of 43 possible EORTC/MSG cases of IFI had definite IFI and the remaining 31 had no evidence of IFI. 18 This supports the suggestion that an aetiology other than IFI may be responsible for the clinical signs and symptoms in one of three probable and five of the 11 possible cases of IFI in which the PCR was negative.
To our knowledge, there is no other prospective study of clinical samples using this methodology. The lower detection limit of this method, using known standards of A. fumigatus and C. albicans, was 20 and 10 CFU/ml, respectively. Variation in the preparation of fungal standards makes comparison of sensitivities between PCR methodologies difficult, and we believe that the detection limit of this assay is satisfactory. In four out of five episodes with proven IFI, sequentially positive PCR results occurred prior to the initiation of antifungal therapy, range 3-28 days, or the microbiological diagnosis of IFI; in the other patient, a single positive PCR result was obtained on the day the blood cultures became positive and antifungal therapy was instituted before further sampling was obtained. Further lowering of the detection threshold may result in an increase in false-positive PCR results with consequent reduction in specificity.
In this study four of the five with proven IFI, and two of the three with probable IFI, were sequentially PCR positive. It is important to note that in the six sequential PCRpositive cases of proven or probable IFI, PCR positivity was not a constant finding, illustrating the importance of prospective, serial screening of at-risk patients.
Sequential positive PCR results were recorded in 29 treatment episodes with no evidence of IFI, and in five of these, the patients went on to develop IFI in subsequent episodes. Our difficulty is to differentiate the true 'false positive' from the positive that indicates that PCR may be a more sensitive indicator of early IFI than current clinical, radiological and laboratory diagnostic methods. Several reasons have been suggested to explain 'false positivity' including subclinical infection, colonization or release of DNA from macrophages. 31, 33 Recovery of the neutrophil count, an important component of the host immune response to fungal infection, and/or the use of empirical therapy may eradicate subclinical infection detected by In episodes with X2 or more consecutive results, the date given is that on which the first of the PCR samples was positive.
d
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PCR. 31, 33, 34 The PPV of only 15% (proven/probable IFI) reflected this 'false positivity', much of which we believe to represent subclinical infection.
Consistently negative PCR results were an excellent predictor that patients would not develop IFI. In a study of PCR-guided therapy in paediatric cancer patients, a reduced mortality was observed for febrile neutropenic patients with IFI and no fungal deaths were recorded in patients with PCR-negative febrile neutropenia. 35 Current management of IFI in haemato-oncology patients relies on empirical antifungal therapy. However, despite significant financial expenditure on antifungal therapy (around 33% of our SCT unit's total drug budget), this strategy is failing with mortality from IA remaining around 80-90%.
Screening of at-risk patients, with a sensitive diagnostic test, will be central to implementing strategies to reduce the incidence and mortality of IFI. Panfungal rather than pathogen-specific PCR using the LightCyclert technique is conceptually more appealing for this task. Panfungal probes enable detection of a wide range of fungal pathogens in a single reaction and, the use of a single pair of probes reduces the cost of the test, making it ideal for rapid screening of high-risk haemato-oncology patients.
We have shown real-time panfungal PCR is a sensitive technique. Sequential PCR positivity precedes the administration of empirical therapy in the majority of cases and results suggest that 'false positivity' may be an indicator of subclinical infection. Institution of antifungal therapy when the fungus burden is low may have significant implications for the management of patients at risk of IFI in terms of duration of antifungal treatment, therapeutic outcome and cost. Prospective screening of high and intermediate-high risk haemato-oncology patients using real-time panfungal PCR may direct the appropriate use of early, pre-emptive antifungal therapy. Furthermore, due to the excellent NPV of the assay, empirical antifungal therapy may be confidently withheld in patients with ARNF who have no other EORTC/MSG evidence of IFI and are persistently PCR negative. This strategy may significantly reduce the use of empirical antifungal therapy in at-risk patients with ARNF.
The development of panfungal PCR and its incorporation into new management strategies has the potential to stimulate a major change in clinical practice, shifting the emphasis of antifungal use from late empirical to early preemptive therapy. The effectiveness of this strategy in haemato-oncology patients requires evaluation in a randomised, comparative trial of PCR-directed vs empirical antifungal therapy.
